These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 16719816

  • 1. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG.
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P, Dubroqua S, Yee BK.
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [Abstract] [Full Text] [Related]

  • 5. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K, Aoki T, Shimazaki Y.
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [Abstract] [Full Text] [Related]

  • 6. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.
    Chen HH, Stoker A, Markou A.
    Psychopharmacology (Berl); 2010 May; 209(4):343-50. PubMed ID: 20217053
    [Abstract] [Full Text] [Related]

  • 7. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.
    Behav Brain Res; 2015 Feb 01; 278():186-92. PubMed ID: 25300471
    [Abstract] [Full Text] [Related]

  • 8. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM.
    Curr Opin Pharmacol; 2006 Feb 01; 6(1):75-81. PubMed ID: 16376148
    [Abstract] [Full Text] [Related]

  • 9. Targeting glutamate synapses in schizophrenia.
    Field JR, Walker AG, Conn PJ.
    Trends Mol Med; 2011 Dec 01; 17(12):689-98. PubMed ID: 21955406
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM, Williams R, Lindsley CW.
    Curr Opin Mol Ther; 2008 Dec 01; 10(6):591-601. PubMed ID: 19051137
    [Abstract] [Full Text] [Related]

  • 12. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex.
    Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B.
    Biol Psychiatry; 2007 Oct 01; 62(7):739-46. PubMed ID: 17511968
    [Abstract] [Full Text] [Related]

  • 13. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
    Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.
    Curr Top Med Chem; 2013 Oct 01; 13(1):26-54. PubMed ID: 23409764
    [Abstract] [Full Text] [Related]

  • 14. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.
    Matosin N, Newell KA.
    Neurosci Biobehav Rev; 2013 Mar 01; 37(3):256-68. PubMed ID: 23253944
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.